 Tiziana Life Sciences Ltd NASDAQ:TLSA said it has published a scientific article in the peer-reviewed journal Frontiers in Immunology, showing a favorable safety profile for intranasally administered foralumab and immunological activity in humans. Entitled Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8 T cell function and induces a regulatory response in T cells in human subjects, the findings support Tizianas intranasal foralumab monoclonal antibody platform as a new modality for treating autoimmune and central nervous system CNS diseases. 